NASDAQ:CKPT

Checkpoint Therapeutics - CKPT Stock Forecast, Price & News

$5.67

+0.20 (+3.66%)

(As of 02/8/2023 12:00 AM ET)

Add

Compare

Today's Range: $5.40
▼
$5.67
50-Day Range: $0.52
▼
$7.73
52-Week Range: $3.56
▼
$24.10

Volume: 84,162 shs
Average Volume: 253,416 shs
Market Capitalization: $52.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.00

Institutional Ownership

Checkpoint Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 702.5% Upside
$45.50 Price Target
Short Interest: Healthy
4.27% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.63
Upright™ Environmental Score
News Sentiment: 0.21
Based on 4 Articles This Week
Insider Trading: Selling Shares
$102,359 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($5.91) to ($4.81) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

147th out of 1,026 stocks

Pharmaceutical Preparations Industry

57th out of 504 stocks

3.5

Analyst's Opinion

Consensus Rating
Checkpoint Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $45.50, Checkpoint Therapeutics has a forecasted upside of 702.5% from its current price of $5.67.
Amount of Analyst Coverage
Checkpoint Therapeutics has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
4.27% of the float of Checkpoint Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Checkpoint Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Checkpoint Therapeutics has recently decreased by 13.33%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Checkpoint Therapeutics does not currently pay a dividend.
Dividend Growth
Checkpoint Therapeutics does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Checkpoint Therapeutics has received a 62.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Checkpoint Therapeutics is -0.63.

2.3

News and Social Media Coverage

News Sentiment
Checkpoint Therapeutics has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Checkpoint Therapeutics this week, compared to 1 article on an average week.
Search Interest
9 people have searched for CKPT on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Checkpoint Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Checkpoint Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $102,359.00 in company stock.
Percentage Held by Insiders
Only 4.30% of the stock of Checkpoint Therapeutics is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Checkpoint Therapeutics are expected to grow in the coming year, from ($5.91) to ($4.81) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Checkpoint Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Checkpoint Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Checkpoint Therapeutics has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Checkpoint Therapeutics (NASDAQ:CKPT) Stock

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.

Receive CKPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Checkpoint Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CKPT Stock News Headlines

February 5, 2023 | americanbankingnews.com

William Garrett Gray Sells 3,154 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Stock

February 5, 2023 | americanbankingnews.com

James F. Oliviero III Sells 10,261 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Stock

February 9, 2023 | Tradewins (Ad)

New Years, New Ways To Trade!

If you’ve been considering options trading but don’t know where to start, trading champion Chuck Hughes’ coveted guide, “Options Trading Made Easy” is for you! Free for a limited time, this guide could help 2023 become your most profitable year yet! Click here for a free copy now!

February 1, 2023 | marketwatch.com

Immune Checkpoint Blockers Market: Prosperous Growth Opportunities 2023 with Business Expansion Plans, Top Players Forecast to 2027

January 18, 2023 | marketwatch.com

Global Immune Checkpoint Inhibitors Market Size 2023 with End-user Industries, Segments Covered in the Report, Report Contains (113) Pages

January 17, 2023 | benzinga.com

Checkpoint Therapeutics to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

January 10, 2023 | seekingalpha.com

Checkpoint Therapeutics: An Updated Analysis

January 4, 2023 | finance.yahoo.com

Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

February 9, 2023 | Vantage Point (Ad)

3 Secrets To Consistent Trading Success

Don't get caught in the trap of standing on the sidelines of intermarket correlation. The truth is that it’s impossible for you (or any human) to visualize and calculate complicated intermarket causations. Learn with A.I. which global markets have the most influence on a target market. Save a Seat for This Free Live Training.

January 1, 2023 | finance.yahoo.com

Individual investors in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) are its biggest bettors, and their bets paid off as stock gained 36% last week

December 24, 2022 | msn.com

Citations, arrest made following RPD's DUI/Driver's License Checkpoint on Thursday

December 23, 2022 | usnews.com

Pakistan Suicide Car Bombing Kills One Police Official, Injures Others

December 6, 2022 | marketwatch.com

Checkpoint Therapeutics Shares Dive 10% on Pending 1-for-10 Reverse Split

December 5, 2022 | finance.yahoo.com

Checkpoint Therapeutics Announces Reverse Stock Split

November 8, 2022 | finance.yahoo.com

Checkpoint Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

November 7, 2022 | benzinga.com

Sensei Biotherapeutics to Host Virtual Key Opinion Leader Webinar, "Lessons from VISTA: New Strategies to Address an Important Immune Checkpoint"

November 4, 2022 | marketwatch.com

Checkpoint Inhibitors for Treating Cancer Market 2022-2026 Competition to Heat up With Innovative Technologies Going Mainstream Globally

November 2, 2022 | usnews.com

Palestinian Shot Dead in Car-Ramming Attack at West Bank Checkpoint

October 26, 2022 | msn.com

Preston County Sobriety Checkpoint planned for November

September 17, 2022 | nasdaq.com

We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

September 8, 2022 | seekingalpha.com

Checkpoint: Strong Data, But Comes With Risks

September 7, 2022 | bizjournals.com

Checkpoint Surgical names new CEO as founder Len Cosentino steps aside

August 26, 2022 | msn.com

Burbank Police to Set Up DUI Checkpoint on Saturday Night

August 16, 2022 | bizjournals.com

Waltham biotech Checkpoint Therapeutics stops cancer study due to Ukraine war

August 12, 2022 | marketwatch.com

Checkpoint Swings to 2Q Loss, Ends Trial Due to War in Ukraine

August 9, 2022 | marketwatch.com

Immune Checkpoint Inhibitors Market Trends 2022 Sales, Top Vendors, Growth Insights, Segments, Size, Industry Share and Forecast to 2029

July 19, 2022 | marketwatch.com

Global Immune Checkpoint Inhibitors Market 2022 Opportunity Analysis, Comprehensive Insights, CAGR Status and Future Opportunity Assessment by 2028

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CKPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Checkpoint Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CKPT Company Calendar

Last Earnings: 11/04/2021
Today: 2/08/2023
Next Earnings (Estimated): 3/27/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CKPT
CUSIP: N/A
CIK: 1651407
Web: www.checkpointtx.com
Phone: (781) 652-4500
Fax: N/A
Employees: 14
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $45.50
High Stock Price Forecast: $76.00
Low Stock Price Forecast: $15.00
Forecasted Upside/Downside: +164.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($8.70)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-56,670,000.00
Net Margins: -53,252.24%
Pretax Margin: -53,252.24%
Return on Equity: -508.89%
Return on Assets: -187.37%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.94
Quick Ratio: 0.94

Sales & Book Value

Annual Sales: $270,000.00
Price / Sales: 195.30
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.43 per share
Price / Book: 1.65

Miscellaneous

Outstanding Shares: 9,300,000
Free Float: 8,902,000
Market Cap: $52.73 million
Optionable: Not Optionable
Beta: 1.49

Key Executives

James F. Oliviero
President, Chief Executive Officer & Director

William Garrett Gray
Chief Financial Officer, Secretary & Treasurer

Jaclyn Jaffe
Head-Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CKPT Stock - Frequently Asked Questions

Should I buy or sell Checkpoint Therapeutics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CKPT shares.
View CKPT analyst ratings or view top-rated stocks.
What is Checkpoint Therapeutics' stock price forecast for 2023?: 2 brokers have issued twelve-month price targets for Checkpoint Therapeutics' shares. Their CKPT share price forecasts range from $15.00 to $76.00. On average, they predict the company's share price to reach $45.50 in the next year. This suggests a possible upside of 702.5% from the stock's current price.
View analysts price targets for CKPT or view top-rated stocks among Wall Street analysts.
How have CKPT shares performed in 2023?: Checkpoint Therapeutics' stock was trading at $5.11 on January 1st, 2023. Since then, CKPT shares have increased by 11.0% and is now trading at $5.67.
View the best growth stocks for 2023 here.
When is Checkpoint Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our CKPT earnings forecast.
How were Checkpoint Therapeutics' earnings last quarter?: Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.14) EPS for the quarter, meeting analysts' consensus estimates of ($0.14). The firm earned $0.03 million during the quarter, compared to the consensus estimate of $0.30 million. Checkpoint Therapeutics had a negative trailing twelve-month return on equity of 508.89% and a negative net margin of 53,252.24%.

What other stocks do shareholders of Checkpoint Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Checkpoint Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX), Kadmon (KDMN) and Rigel Pharmaceuticals (RIGL).
What is Checkpoint Therapeutics' stock symbol?: Checkpoint Therapeutics trades on the NASDAQ under the ticker symbol "CKPT."
Who are Checkpoint Therapeutics' major shareholders?: Checkpoint Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Park Avenue Securities LLC (0.50%), Envestnet Asset Management Inc. (0.30%), Ironwood Investment Management LLC (0.14%), Emfo LLC (0.08%), Bartlett & Co. LLC (0.05%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include James F Oliviero III and William Garrett Gray.
View institutional ownership trends.
How do I buy shares of Checkpoint Therapeutics?: Shares of CKPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Checkpoint Therapeutics' stock price today?: One share of CKPT stock can currently be purchased for approximately $5.67.
How much money does Checkpoint Therapeutics make?: Checkpoint Therapeutics (NASDAQ:CKPT) has a market capitalization of $52.73 million and generates $270,000.00 in revenue each year. The company earns $-56,670,000.00 in net income (profit) each year or ($8.70) on an earnings per share basis.
How can I contact Checkpoint Therapeutics?: Checkpoint Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The official website for the company is www.checkpointtx.com. The company can be reached via phone at (781) 652-4500 or via email at investor@chimerareit.com.

This page (NASDAQ:CKPT) was last updated on 2/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Checkpoint Therapeutics - CKPT Stock Forecast, Price & News

Checkpoint Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Checkpoint Therapeutics (NASDAQ:CKPT) Stock

CKPT Stock News Headlines

CKPT Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CKPT Stock - Frequently Asked Questions

Overall MarketRank^™